D.E. Shaw & Co’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

D.E. Shaw & Co’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,000	Closed	-$526K	–	5512
2021 Q3	$526K	Hold	10,000	–	–	﹤0.01%	4058
2021 Q2	$689K	Hold	10,000	–	–	﹤0.01%	3839
2021 Q1	$771K	Buy	+10,000	New	+$921K	﹤0.01%	3287
2020 Q4	–	Sell	-10,000	Closed	-$1.42M	–	4003
2020 Q3	$1.42M	Hold	10,000	–	–	﹤0.01%	2626
2020 Q2	$1.97M	Hold	10,000	–	–	﹤0.01%	2416
2020 Q1	$1.96M	Hold	10,000	–	–	﹤0.01%	2186
2019 Q4	$2.07M	Buy	+10,000	New	+$1.85M	﹤0.01%	2435

Other funds holding LKFT

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co's LKFT Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 22% in Q1 2026, selling an estimated $1.96M and leaving 215,718 shares worth $6.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1983.

D.E. Shaw & Co first reported a position in LKFT in Q3 2018 and has held it in 26 quarters since. The position peaked at $8.99M in Q4 2025. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

D.E. Shaw & Co held 215,718 shares of Lakefront Biotherapeutics American Depositary Shares worth $6.47M as of Q1 2026.
D.E. Shaw & Co sold 59,281 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $1.96M.
Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1983 holding.
D.E. Shaw & Co first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2018 and has held it in 26 quarters since.
D.E. Shaw & Co's Lakefront Biotherapeutics American Depositary Shares position peaked at $8.99M in Q4 2025.
90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.